Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR.MUC1.TR2.41BB T cells
- Development stage
- Preclinical
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR.MUC1.TR2.41BB T cells is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to treat solid tumors, specifically breast cancer. Developed by researchers at the Baylor College of Medicine, these T cells are genetically engineered to express a CAR targeting tumor-associated mucin 1 (MUC1) alongside a novel chimeric costimulatory receptor (TR2.41BB) that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TR2 / TNFRSF10B) expressed on myeloid-derived suppressor cells (MDSCs). By binding to TR2, the costimulatory receptor induces apoptosis in immunosuppressive MDSCs, thereby remodeling the tumor microenvironment and restoring the cytotoxic activity of the CAR T cells. Simultaneously, this interaction triggers intracellular 4-1BB (CD137) costimulatory signaling within the T cells, enhancing their proliferation, persistence, and anti-tumor efficacy.
- Other names
- CAR.MUC1.TR2.4-1BB T cellsCAR.MUC1/TR2.41BB T cellsMUC1.TR2.4-1BB CAR-T cellsMUC-1.TR2.4-1BB CAR-T cellsMUC 1.TR2.4-1BB CAR-T cellsMUC1.TR2.4-1BB CARTsMUC-1.TR2.4-1BB CARTsMUC 1.TR2.4-1BB CARTs
Beyond the preview
Go deeper on CAR.MUC1.TR2.41BB T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR.MUC1.TR2.41BB T cells.